ReviewExperientia supplementum (2012)
Metabolomic-Based Methods in Diagnosis and Monitoring Infection Progression.
Review in Experientia supplementum (2012). The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed.
- Review
- Distinct systemic metabolic phenotypes associated with blood culture positivity and bacterial etiology in community-acquired pneumonia (CAP).Frontiers in cellular and infection microbiology · 2026Article
- A Pilot Metabolomic Study for DiagnosingInternational journal of molecular sciences · 2025Article
- Metabolomics strategy for diagnosing urinary tract infections.Nature communications · 2025Article
- Identification of trans-genus biomarkers for early diagnosis of intestinal schistosomiasis and progression of gut pathology in a mouse model using metabolomics.PLoS neglected tropical diseases · 2024Article
- Metabolomics Approaches for the Diagnosis, Treatment, and Better Disease Management of Viral Infections.Metabolites · 2023Review
- Metabolomic profiling of bacterial biofilm: trends, challenges, and an emerging antibiofilm target.World journal of microbiology & biotechnology · 2023Review
- Untargeted serum metabolomics analysis of Trichinella spiralis-infected mouse.PLoS neglected tropical diseases · 2023Article
- Diagnostic biomarker panels of osteoarthritis: UPLC-QToF/MS-based serum metabolic profiling.PeerJ · 2023Article
- Article
- Comparison of freeze-thaw and sonication cycle-based methods for extracting AMR-associated metabolites fromFrontiers in microbiology · 2023Article
- Using a multiomics approach to unravel a septic shock specific signature in skeletal muscle.Scientific reports · 2022Article
- Tuberculous Granuloma: Emerging Insights From Proteomics and Metabolomics.Frontiers in neurology · 2022Review
- Untargeted serum metabolomic profiling for early detection ofFrontiers in cellular and infection microbiology · 2022Article
- Metabolomics reveal alterations in arachidonic acid metabolism in Schistosoma mekongi after exposure to praziquantel.PLoS neglected tropical diseases · 2021Article
- Diagnostic Potential of the Plasma Lipidome in Infectious Disease: Application to Acute SARS-CoV-2 Infection.Metabolites · 2021Article
- Metabolomics in infectious diseases and drug discovery.Molecular omics · 2021Review
- Metabolomics in the Diagnosis and Prognosis of COVID-19.Frontiers in genetics · 2021Review
- Differential Markers of Bacterial and Viral Infections in Children for Point-of-Care Testing.Trends in molecular medicine · 2020Review
- Integrative Metabolomics to Identify Molecular Signatures of Responses to Vaccines and Infections.Metabolites · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A robust biomarker screening and validation is crucial for overcoming the current limits in the clinical management of infectious diseases. In this chapter, a general workflow for metabolomics is summarized. Subsequently, an overview of the major contributions of this omics science to the field of biomarkers of infectious diseases is discussed. Different approaches using a variety of analytical platforms can be distinguished to unveil the key metabolites for the diagnosis, prognosis, response to treatment and susceptibility for infectious diseases. To allow the implementation of such biomarkers into the clinics, the performance of large-scale studies employing solid validation criteria becomes essential. Focusing on the etiological agents and after an extensive review of the field, we present a comprehensive revision of the main metabolic biomarkers of viral, bacterial, fungal, and parasitic diseases. Finally, we discussed several articles which show the strongest validation criteria. Following these research avenues, precious clinical resources will be revealed, allowing for reduced misdiagnosis, more efficient therapies, and affordable costs, ultimately leading to a better patient management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.